Oncolytics Biotech Inc. is a Canadian company headquartered in Calgary, Alberta, that is developing an intravenously delivered immuno-oncolytic virus called pelareorep for the treatment of solid tumors and hematological malignancies.
Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus that: induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses.
Traded as: TSX: ONC, NASDAQ: ONCY
Industry: Biopharmaceutical
Founded: 1998 Calgary, Alberta, Canada
Headquarters: Calgary, Alberta, Canada
Products REOLYSIN, a first-in-class intravenously delivered immuno-oncolytic virus (IOV) for the treatment of solid tumors and hematological malignancies.
Website: www.oncolyticsbiotech.com